Dr. Pal on the Mutational Burden in Bladder Cancer

Video

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

There are multiple data sets that suggest that PD-L1 status has varying potential in terms of predictive capabilities across the spectrum of agents that are approved for patients with metastatic urothelial cancer, says Pal.

Tumor mutational burden may be relevant in selecting ideal pairings of drugs, explains Pal.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic